Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post‐translational modification of beta 2 glycoprotein I
Authors:
Open Access
- 22 July 2011
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9, 275-282
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2‐glycoprotein IArthritis & Rheumatism, 2011
- β2-glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse modelBlood, 2011
- Redox control of β2‐glycoprotein I–von Willebrand factor interaction by thioredoxin‐1Journal of Thrombosis and Haemostasis, 2010
- Autoimmune-mediated atherothrombosisLupus, 2008
- Anti‐beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal womenJournal of Thrombosis and Haemostasis, 2007
- β2-Glycoprotein I inhibits von Willebrand factor–dependent platelet adhesion and aggregationBlood, 2007
- Binding of β2–glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cellsBlood, 2005
- Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazepBlood, 2004
- Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (β2-glycoprotein I)Life Sciences, 2001
- T cells that are autoreactive to β2-glycoprotein I in patients with antiphospholipid syndrome and healthy individualsArthritis & Rheumatism, 2000